Despite improvements in gene delivery technology, transient expression of plasmid DNA has limited the efficacy of nonviral vectors applied to cancer gene therapy. We previously developed plasmid DNA vectors capable of transgene integration and long-term expression in human glioblastoma cells by utilizing the Sleeping Beauty (SB) transposable element. In this study, we compared the efficacy of interferon gamma (IFN-g) immunogene therapy using episomal or SB vectors in a syngeneic GL261 glioma model. Gene delivery was achieved by intratumoral convection-enhanced delivery of DNA/polyethylenimine complexes. Only mice treated with SB transposase-encoding DNA to facilitate chromosomal integration exhibited a significant increase in survival (Po0.05). SBmediated intratumoral gene transfer caused sustained IFN-g expression assessed by reverse transcription-polymerase chain reaction, of both vector-derived and endogenous IFN-g, whereas expression following episomal plasmid gene transfer was undetectable within 2 weeks. Median survival was enhanced further when SB-mediated IFN-g gene transfer was combined with CpG oligodeoxynucleotides as adjuvant therapy. Prolonged survival positively correlated with tumor regression measured by in vivo bioluminescent imaging, and enhanced T-cell activation revealed by the ELISPOT assay. SB appears to improve the efficacy of cytokine gene therapy using nonviral vectors by enhancing the duration of transgene expression.
Introduction
Achieving long-lasting gene transfer into mitotic tumor cells and tumor-associated stroma remains a central challenge to nonviral cancer gene therapy approaches (see Lam and Breakefield 1 and Ohlfest et al. 2 for review). Even though the goal of cancer gene therapy is often tumor cell death, there is likely a threshold of sustained and therapeutic gene expression that is required to cause tumor regression. In contrast to nonviral vectors, viral vectors have often facilitated sustained expression of antitumor proteins from a single administration in murine models. [3] [4] [5] A typical approach to overcoming the transient expression of nonviral gene transfer has been repeated administration, which has produced encouraging results in patients with metastatic melanoma 6 and renal cell carcinoma. 7 New approaches that allow sustained gene expression could potentially reduce the number of administrations required, and increase the efficacy of nonviral cancer gene therapy vectors.
Glioblastoma Multiforme (GBM) is fatal brain tumor that is considered a good target for gene therapy because it rarely metastasizes beyond the brain, thereby allowing local delivery and concentration of vector within peritumoral areas. 3 Despite advances in surgery, radiation and chemotherapy, the prognosis for GBM patients remains dismal with a median survival of 15 months and 2-year survival rate below 27%. 8 Gene therapy has shown modest efficacy in GBM patients, 3, 9, 10 but curative therapy remains an elusive goal.
We previously demonstrated that the Sleeping Beauty (SB) transposable element achieves chromosomal integration and long-term expression in human glioblastoma xenografts from a plasmid DNA substrate. 11 SB belongs to the Tc1/mariner superfamily of transposons and mediates cut-and-paste integration of the transposon into TA dinucleotides in the host cell genome 12 (reviewed by Izsvak and Ivics 13 ). The gene encoding the transposase enzyme, which mediates excision and integration of the transposon DNA, can be provided on a separate (trans) or the same (cis) plasmid DNA molecule. SB-mediated antiangiogenic gene transfer significantly increased survival of immunodeficient mice bearing established GBM xenografts, whereas treatment with the identical genes delivered as episomal plasmid failed. 14 In this study, we sought to determine if SB-mediated gene transfer could improve the efficacy of immunogene therapy by facilitating sustained cytokine expression in glioma-bearing mice. We chose to study interferon gamma (IFN-g) gene transfer owing to its ability to upregulate expression of major histocompatibility complex (MHC) I, enhance natural killer (NK) cell and T cell activity, inhibit tumor cell growth directly and inhibit angiogenesis. [15] [16] [17] [18] This study revealed that SB-mediated gene transfer into GL261 murine glioma resulted in enhanced IFN-g expression that was associated with a significant increase in survival compared with administering IFN-g-encoding DNA without SB. The survival benefit was increased further when SB-mediated IFN-g gene transfer was co-administered with CpG oligodeoxynucleotides (ODN) that activate toll-like receptor nine and potentiate inflammation. 19 This is the first demonstration that transposable elements can enhance the efficacy of nonviral cytokine gene therapy for malignant tumors.
Materials and methods
Cell lines, transfection and ELISA GL261 is an aggressive glioma cell line that is derived from C57BL/6 mice. GL261 cells were obtained from Dr P Shrikant (Center for Immunology, Minneapolis, MN). GL261 cells were co-transfected with pKT2/CLPLuc-IRES-Puro and pPGK-SB13, then selected in 400-ng/ ml puromycin to generate luciferase-stable GL261 cells. Transfection was conducted as described previously.
14 A single clone that was isolated by limiting dilution was passaged in vivo by intracranial tumor inoculation, followed by tumor dissociation and re-selection in 400-ng/ml puromycin to generate the GL261-Luc cell line used in these studies. The GL261-Luc cells were tested for tumorogenicity by intracerebral transplantation into C57BL/6 mice (10 000 cells/mouse); untreated animals typically became moribund owing to tumor progression 22-32 days after tumor implantation. GL261 and GL261-Luc cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin at 371C and 5% CO 2 .
In the transfection experiment (in Figure 1b) 1 Â 10 5 GL261-Luc cells were seeded in six-well plates in triplicate and 24 h later co-transfected with 1 mg of pKT2/CLP-IFNg and 1 mg of phosphoglycerate kinase (PGK)-SB13 or pT2C-Luc (no SB control); the culture supernatants were collected at days 1, 3, 5 and 7 after the transfection and stored at À801C. IFN-g was measured in the supernatant using mouse IFN-g Elisa kit (Biolegend, San Diego, CA) according to the manufacturer's protocol. Briefly, a 96-well plate was coated with anti-mouse IFN-g antibody at 41C overnight and blocked with assay buffer; after washing, a standardized IFN-g solution or cell culture supernatants were added to the wells. Following 2 h of incubation the plate was washed. Biotin labeled detection antibody and diluted avidin horseradish peroxidase were added; after 30 min of incubation and the final washing, the color reaction was developed with tetramethylbenzidine (TMB) substrate solution and stopped after 10 min with H 2 SO 4 . The plate was then read at 450 nm using a EL311 plate reader (Biotek, Winooski, VT). Cytokine production was expressed as ng of IFN-g/ml7s.e. Sleeping beauty-enhanced cytokine gene therapy A Wu et al
In vitro cytokine treatment, flow cytometry and cell viability assay For detection of MHC I and II expression, GL261-Luc cells were treated with the indicated concentrations of mIFN-g (R&D systems, Minneapolis, MN) for 24 h, then harvested by trypsinization and resuspended in fluorescence-activated cell sorting (FACS) buffer (phosphatebuffered saline (PBS), 1% bovine serum albumin, 0.05% NaN 3 ). The cells were then incubated with phycoerythrin (PE)-labeled anti-MHC I (anti-mouse H-2Kb/H-2Db, Biolegend, San Diego, CA) and anti-MHC II antibodies (anti-mouse I-Ab, BD Biosciences, San Jose, CA) or with PE-labeled rat isotype IgG2a (BD Biosciences, San Jose, CA) as a control at 41C for 45 min. After incubation, cells were washed twice with FACS buffer followed by centrifugation at 300 g for 5 min and analyzed on BD FACStation (BD Biosciences, San Jose, CA).
To investigate the effect of mIFN-g on the proliferation of GL261-Luc cells, GL261-Luc cells were plated at a density of 5000 cells/well in triplicate in 96-well plates and increasing concentrations of mIFN-g were added; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed using the CellTiter 96 Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI) at days 1, 3, 5 according to the manufacturer's instructions. Cell viability data were measured with a microplate reader EL311 (Biotek, Winooski, VT) at 570 nm.
Plasmid vectors
The 'T2' in the vector name refers to a modified transposon IR/DR DNA sequence that lead to increased integration efficiency. 20 The pKT2/CLP vector (empty vector control) was a kind gift from Dr A Geurts (University of Minnesota). The pKT2/CLP-Luc-IRESPuro vector used facilitates expression of firefly luciferase and puromycin resistance proteins from a single mRNA and was provided by Dr Andy Wilbur (University of Minnesota). The pT2-Luc vector has been described previously. 11 Hyperactive mutants of the SB transposase enzyme have been generated by site directed polymerase chain reaction (PCR); [20] [21] [22] [23] in this study 'SB13', which pertains to K33A and T83A mutations in the original SB10 gene (first described by Yant et al. 21 ), was expressed under the control of the PGK promoter in pPGK-SB13. A 0.5 kb DNA fragment containing the mIFN-g cDNA was excised from pORF5-mIFN-g (Invivogen, San Diego, CA) as a NcoI/SwaI fragment, and ligated into pKT2/ CLP as a NcoI/MscI fragment to generate pKT2/CLPmIFN-g. The plasmid was verified using restriction endonuclease digestion and agarose gel electrophoresis.
Mice, surgery, imaging and gene therapy Six-to 7-week-old female C57BL/6 mice were purchased from Jackson Laboratory and were maintained in a specific pathogen free facility according to the guidelines of the University of Minnesota Animal Care and Use Committee (IACUC). Luciferase in vivo imaging was conducted as described previously. 14 For intracranial tumor inoculations and gene delivery, animals were deeply anesthetized with a ketamine/ xylazine cocktail solution (53.7 mg/ml ketamine, 9.26 mg/ml xylazine) delivered at 1 ml/kg. GL261-Luc cells (10 000) in 1 ml of PBS were implanted stereotactically into the right striatum; coordinates were 2.2 mm to the right, 0.5 mm posterior of the bregma and 3 mm deep from the cortical surface of the brain. Cells were injected slowly for 3 min with a Hamilton syringe to diminish backflow; the needle was left in place for 1 min after injection, and then slowly withdrawn. The hole in the skull was then closed with bone wax, the incision was sutured and the mice were returned to their housing area when they regained consciousness.
Gene therapy was administered on day 3 and again on day 6 after tumor inoculation by slow infusion into the identical coordinates where the tumor was implanted ( Figure 4) ; in a second experiment gene therapy was administered on day 3, and CpG ODN was administered on day 6 ( Figure 5 ). A final volume of 5 ml was infused over 20 min using a microinjection pump (CM100, Carnegie Medicine, Stockholm, Sweden). DNA/polyethylenimine (PEI) complexes were prepared as described; 
RNA extraction and RT-PCR analysis
To detect the expression of IFN-g, 18 mice were inoculated with GL261-Luc cells as described above, and administered saline (six mice), IFN-g with SB (six mice) or IFN-g without SB (six mice) 3 days after inoculation. Two mice from each group were killed on days 7, 14 and 21 after gene transfer. The mice were quickly perfused with saline and the brains were removed and flash frozen in liquid nitrogen, then cut on a cryostat at a thickness of 10 mm (using a new blade for each sample to avoid trans-contamination). Sections containing tumor visible to the naked eye were collected and kept at À801C for RNA extraction. Total RNA was extracted from the sections by using RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. A total of 300 ng of RNA template was used for reverse transcription (RT)-PCR.
RT-PCR was performed using a 9700 geneamp PCR machine (Applied Biosystem, Foster City, CA). PCR reactions were setup in a final volume of 25 ml using the superscriptIII one-step RT-PCR kit (Invitrogen, Carlsbad, CA). After the RT-step of 501C for 30 min and initial step of 15 min at 941C, the cDNA PCR amplification reaction consisted of 35 cycles of 30 s at 941C, 30 s at 551C and 40 s at 681C, followed by a final step of 7 min at 681C. The PCR products were then run on a 0.8% gel and Sleeping beauty-enhanced cytokine gene therapy A Wu et al stained with Gelstar (Cambrex, Baltimore, MD) to visualize nucleic acid. For RT-PCR, two exon-specific sets of primers were designed based on the plasmid mIFN-g sequence (vectorspecific) and the endogenous mIFN-g mRNA sequence.
As additional controls, no RNA was added to the reaction (water), or the RT amplification step of 30 min at 501C was omitted (No RT). The exonspecific, vector-specific primers used were FWD: 5 0 -TTCTGCCTTCTCCCTCCTGT-3 0 , and REV: 5 0 -GGCCTGATTGTCTTTCAAGA-3 0 . The exon-specific primers used for the endogenous mIFN-g mRNA were FWD: 5 0 -CCTAGAGAAGACACATCAGC-3 0 , and REV: 5 0 -GAGATAATCTGGCTCTGCAG-3 0 . Housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific) primers were used to evaluate relative RNA template concentrations between samples; FWD, 5 0 -GTGGCAAAGTGGAGATTGTT-3 0 , and REV:
Immunohistochemistry and histopathologic analysis Brain tissue for histological examination was obtained from moribund mice 3-7 weeks following treatment. For immunohistochemistry, 30 mm sections were coronally cut using a JUNG CM3000 cryostat machine (IMEB Inc., San Macros, CA). After washing in TBS (Tris-buffered saline, PH 7.4), endogenous peroxidase activity was blocked with 3% H 2 O 2 and 30% MeOH. After blocking (5% normal donkey serum, 0.03% Triton X-100 in TBS) for 1 h, the sections were stained with rat anti-mouse CD4 (Serotec Labs, Oxford, UK, 1:200) or rat anti-mouse CD8a (Serotec Labs, Oxford, UK 1:50) primary antibody at 41C overnight. Sections that were not stained with primary antibody were used as controls, and no significant staining was observed (not shown). Primary antibody was then detected with biotinylated anti-rat IgG (Vector laboratories, Burlingame, CA) followed by incubation with vectastain ABC reagent (Vector Laboratories, Burlingame, CA), and colorimetric detection with the substrate chromogen diaminobenzidine (Vector Laboratories, Burlingame, CA 
Enzyme-linked immunosorbent spot (ELISPOT) assay
For the ELISPOT assay, 9 mice were inoculated and treated with saline, mIFN-g (SB) or mIFN-g (SB) combined with CpG ODN (N ¼ 3/group) as described above. Seven days after the last treatment, all mice were killed and the cervical lymph nodes were removed; lymph node cells were released using gentle pressure with a 3-ml syringe barrel. The ELISPOT assay was performed using a mIFN-g ELISPOT kit (Cell sciences, Canton, MA) according to the manufacturer's instructions. Briefly, a polyvinylidine difluoride 96-well plate was coated with capture antibody at 41C overnight and blocked with 2% skim milk for 2 h. After washing, lymph node cells were plated at a concentration of 5 Â 10 5 /well and stimulated with 5 Â 10 4 GL261-Luc or GL261-WT cells for 48 h at 371C and 5% CO 2 . Tumor cells were incubated in 100 mg/ml mitomycin (Fisher Bioreagents, Fair Lawn, NJ) for 45 min before mixing with cells harvested from the lymph nodes. After incubation, plate membranes were vigorously washed with PBS-0.1% Tween 20 to remove cells and debris; detection antibody was then added and incubated at 371C for 1.5 h. After washing with PBS-0.1% Tween 20, 100 ml of streptavidin alkaline phosphatase (1:5000 dilution) was distributed into each well for 1 h at 371C. The wells were washed four times with PBS-0.1% Tween 20 before adding 100 ml BCIP/NBT buffer and incubated at RT for 10 min. The plates were finally rinsed three times with distilled water and air-dried and spots were counted by using a microscope (Lieca Microsystem Inc., Bannockburn, IL). Lymph node cells from naı¨ve mice (N ¼ 3) were also analyzed as a control.
Statistical analysis
Statistical comparisons between different data values were carried out using ANOVA, and ad hoc comparisons using two-tailed Student's t-test with sigmastat software (Systat Software Inc., San Jose, CA); P-values p0.05 were considered significant. Differences in animal survival between treatment groups were evaluated by log-rank statistical analysis with sigmastat software; only P-values p0.05 were considered significant.
Results

SB-mediated gene transfer enhanced stable IFN-g expression in vitro
A transposon vector was constructed in which the expression of mouse (m) IFN-g was regulated by a strong cytomegalovirus (CMV) enhancer/EF1-a chimeric promoter (pKT2/CLP-mIFN-g; Figure 1a ). In order to determine if SB-mediated gene transfer could enhance mIFN-g expression in vitro, GL261 cells were cotransfected with pKT2/CLP-mIFN-g and pPGK-SB13, or with pKT2/CLP-mIFN-g and a luciferase-encoding plasmid (no-SB control). The amount of mIFN-g was measured by an enzyme-linked immunosorbent assay (ELISA) in the tissue culture supernatant for 1 week. At 24 h after transfection, the levels of measured mIFN-g were nearly identical regardless of whether SB-encoding DNA was co-transfected (Figure 1b) . However, there was a statistically significant increase in mIFN-g measured on days 5 and 7 when SB-encoding was co-transfected relative to the no-SB control (luciferase; Figure 1b) , thereby demonstrating SB enhanced the level stable mIFN-g gene transfer in glioma cells in vitro.
GL261-Luc allows real-time tumor quantification in vivo
We have previously utilized U87 cells that stably express firefly luciferase to measure tumor burden in nude mice
14 This imaging method is useful to determine the time dynamics of tumor regression in response to therapy and confirm that long-term survival is due to treatment and not poor tumor engraftment. In order to utilize this method in C57BL/6 mice, we genetically engineered GL261 cells to stably express luciferase as described in the Materials and methods (GL261-Luc). Intracranial injection of 10 000 GL261-Luc cells caused development of invasive and fatal glioma growth in 100% of mice (Figure 2a) . This is in contrast to many human tumor xenograft models that grow like a spherical metastasis rather than an invasive GBM, such as U87 implanted into the brain of nude mice.
14 Tumor progression to death correlated with measured tumor burden by in vivo imaging (Figures 2c,  4a, 5a) . In order to verify GL261-Luc cells respond to mIFN-g in vitro, their proliferation and expression of MHC I and II was determined by an MTT assay and flow cytometry, respectively. Treatment with mIFN-g significantly reduced the number of viable GL261-Luc cells and upregulated MHC I and II cell surface antigens (Figure   2c-d) . This results is consistent with previous studies that examined the effects of IFN-g on many tumor cell lines including GL261. 16, 17 SB mediates sustained IFN-g expression in vivo that correlates with prolonged survival of murine glioblastoma The effects of SB-mediated mIFN-g intratumoral gene transfer relative to mIFN-g-encoding episomal plasmid were then investigated. Three days after tumor implantation, mice were treated by intratumoral infusion of 2.5 mg of pKT2/CLP-mIFN-g with or without 0.125 mg pPGK-SB13 complexed in PEI, or treated with saline (5 ml volume delivery over 20 min; N ¼ 6/group). Two mice in each group were killed on weeks 1, 2 and 3 after gene therapy; frozen brains were sectioned and RNA was extracted from sections containing appreciable tumor for RT-PCR analysis. RT-PCR conducted on mIFN-gtreated brains revealed robust mIFN-g expression at 1 week after gene transfer, in both SB-and non-SB-treated groups. However, by 2 weeks after gene transfer, Sleeping beauty-enhanced cytokine gene therapy A Wu et al mIFN-g-treated brains that were not treated with SBencoding DNA exhibited no detectable IFN-g expression, whereas sustained mIFN-g expression was detected in SBtreated brains ( Figure 3) . Interestingly, sustained expression of mIFN-g was detected using primers specific to the endogenous mIFN-g mRNA, and treatment with SBencoding DNA was required to sustain expression ( Figure 3 ). These results reveal that SB-mediated mIFNg gene transfer enhances the level of sustained expression compared with episomal plasmid, and that the endogenous cells within the brain reacted by concomitantly expressing mIFN-g. A survival experiment was then conducted to determine if the increase in sustained mIFN-g expression achieved with SB-mediated gene transfer enhanced survival compared with non-SB-treated mice. Mice were intracerebrally inoculated with GL261-Luc cells and treated by intratumoral IFN-g gene transfer on days 3 and 6 with or without SB-encoding DNA; saline and empty-vectortreated mice were used as controls (N ¼ 10/group). In vivo imaging was conducted before treatment (day 1 after inoculation) and every week thereafter. In vivo imaging revealed that mice treated with IFN-g gene transfer (plus SB) exhibited tumor regression compared with mice treated with saline or empty vector (Figure 4a) . However, despite a transient tumor regression, all tumors eventually recurred leading to death (Figure 4b ). Mice treated with IFN-g gene transfer without SB-encoding DNA did not survive significantly longer than saline-treated controls. Log-rank statistical analysis indicated that only mice treated with SB-mediated IFN-g gene transfer had a significant increase in survival (P ¼ 0.039). These results demonstrate that SB-mediated IFN-g gene transfer caused tumor regression and extends survival, whereas the episomal IFN-g vectors failed to demonstrate efficacy.
CpG ODN enhanced the efficacy of SB-mediated IFN-g gene transfer
Previous studies have shown that intracerebral infusion of CpG ODN into mice activates TLR9 signaling in microglial cells, leading to inflammatory cytokine production and modulation of adaptive immunity. 19 CpG ODN has also been shown to have anti-glioma activity in rats bearing syngeneic intracranial glioma 24 and mice bearing GL261 glioma. 25 Based on these previous studies, we investigated if CpG ODN might be an effective adjuvant to IFN-g gene therapy.
Mice inoculated with GL261-Luc cells were treated by intratumoral IFN-g (plus SB) gene transfer on day 3, and again with or without CpG ODN treatment on day 6; saline-treated mice were used as controls (N ¼ 10/group). The combination of IFN-g and CpG ODN caused tumor regression, but all tumors eventually recurred leading to death (as shown by imaging; Figure 5a ). Mice treated with Sleeping beauty-enhanced cytokine gene therapy A Wu et al CpG ODN alone did not survive significantly longer than saline-treated controls (P ¼ 0.76) Log-rank statistical analysis indicated that only mice treated with IFN-g gene transfer (with SB) or CpG ODN plus IFN-g had a significant increase in survival (P ¼ 0.018; Figure 5b ). The combination of CpG ODN and IFN-g gene transfer (with SB) resulted in greater median survival (38 days) compared with mice treated with IFN-g (with SB) alone (33 days; P ¼ 0.032). These results reveal that CpG ODN and SB-mediated IFN-g gene transfer have modest additive benefit to survival, but this is not sufficient to achieve complete cure.
Enhanced inflammation, tumor necrosis and tumor-reactive T cells in treated mice
In order to investigate if prolonged survival correlated with changes in the tumor microenvironment, the brains of mice that survived significantly longer than saline controls were analyzed by H&E staining. In addition, CD4 and CD8 immunohistochemistry was also conducted. Tumors treated with IFN-g gene transfer (with SB) and IFN-g gene transfer (with SB) plus CpG ODN exhibited a marked increase in necrosis compared with empty vector controls: the center of the tumor was completely necrotic, whereas saline-treated tumors contained small focal areas of necrosis ( Figure 6 ). Accordingly, DNA-treated tumors had enhanced CD4 þ and CD8 þ lymphocyte infiltration compared with salinetreated tumors (Figure 6 ). Although these histological analyses demonstrated that prolongation of survival correlated with increased tumor infiltrating lymphocytes, this provided no information regarding the specificity of T-cell activity to the tumor.
To delineate whether treatment merely recruited T cells or if expansion of tumor-reactive T cells had occurred, a smaller cohort of animals was treated with the effective therapies (IFN-g or IFN-g plus CpG) or saline as a control (N ¼ 3/group). Treatment was carried out identically as above (as in Figure 5 ). Seven days after the last intratumoral infusion, all mice were killed and cervical lymph nodes were dissociated. An ELISPOT assay was then conducted to quantify the extent of T-cellmediated IFN-g secretion in response to interaction with GL261 cells in vitro. Lymph cells from naı¨ve mice were also stimulated with GL261 as a control. Only cells harvested from mice treated with IFN-g, or IFN-g plus CpG exhibited a statistically significant increase in IFN-g spots compared with naı¨ve controls (Po0.01), thereby revealing that treatment with either effective approach resulted in generation of tumor-reactive T cells. There was a noticeable, but statistically insignificant increase in the number of measured IFN-g spots using Figure 5 In vivo tumor imaging and survival after CpG or IFN-g therapy. (a) Glioma-bearing mice were treated by intratumoral infusion of PEI/DNA complexes encoding mIFN-g and SB-encoding DNA on day 3, with or without CpG ODN on day 6 after tumor inoculation. Mice treated with saline were used as controls (N ¼ 10/ group). Weekly in vivo imaging was conducted and representative images are shown. Mice treated with CpG plus mIFN-g exhibited the greatest reduction in tumor growth. (b) Survival of mice treated as described in (a). Mice treated with mIFN-g exhibited a significant increase in survival assessed by log-rank statistical analysis (P ¼ 0.018). Mice treated with mIFN-g plus CpG ODN survived significantly longer than mice treated with mIFN-g alone (P ¼ 0.032). Figure 7a ). The results of the ELISPOT assays were nearly identical when the harvested lymphocytes were stimulated with GL261-Luc cells or the parental GL261 cells, indicating that the relevant immunogen was not luciferase (Figure 7b ). Taken together, the histological and ELISPOT analyses demonstrates that treatment with IFN-g, or IFN-g plus CpG resulted in: enhanced tumor necrosis, increased tumor infiltration of CD4 þ and CD8 þ lymphocytes, and that prolongation of survival correlated with generation tumor-reactive T cells as assessed by ELISPOT.
Discussion
The concentration and duration of cytokine expression following gene transfer is likely to play a critical role in therapeutic efficacy. 2 Achieving durable tumor regression using immunogene therapy can be challenging, especially when nonviral vectors are used. Goto et al. 26 have used episomal plasmids encoding interleukin-12 (IL-12) to achieve sustained cure of subcutaneous tumors in mice, but four repeated administrations were required to demonstrate a high level of efficacy. Similarly, repeated administration of an IL-12-encoding plasmid into melanoma patients demonstrated antitumor activity in select patients. 6 However, the concentration of IL-12 in serum was not higher than pretreatment levels for more than 1-2 days after each plasmid administration, again highlighting the transient effects of plasmid vectors. 6 Recently, several recombinase systems have been developed that allow chromsomal integration and long-term expression following a single administration of plasmid DNA, including transposable elements and bacteriophage integrases (see Groth and Calos, 27 and Ivics and Izsvak 28 for review). Intratumoral injection of SB transposon vectors into experimental GBM caused chromosomal transgene integration into TA dinucleotides and long-term expression, whereas episomal gene transfer was transient. 11 We postulated that in order to effectively prime an antitumor immune response, it would be advantageous to achieve long-lasting cytokine expression that persists at therapeutic levels after gene transfer. In this study, we delivered a transposon vector containing the mIFN-g cDNA into GL261 glioma cells, with or without SB-encoding DNA to determine if SB-mediated gene transfer could enhance therapeutic efficacy. SB-mediated IFN-g gene transfer significantly improved the level of sustained IFN-g expression relative to non-integrating plasmid in vitro (Figure 1b ). When applied in vivo by intratumoral convection-enhanced delivery, SB-treated tumors exhibited sustained IFN-g expression for at least 3 weeks, whereas IFN-g expression in non-SB-treated controls was undetectable beyond 1 week (Figure 3) . In vivo tumor imaging revealed that only mice treated with IFN-g and SB-encoding DNA exhibited tumor regression (Figure 4a ), although all tumors eventually relapsed to cause death. In addition, only mice treated with IFN-g and SB-encoding DNA survived significantly longer than empty vector or saline controls (Figure 4b ). Taken together, these results demonstrate that SB-mediated IFN-g gene transfer enhanced transgene expression and therapeutic efficacy relative to non-integrating plasmid DNA in this tumor model.
Interestingly, RT-PCR on RNA extracted from SBtreated tumors revealed upregulation of IFN-g expression from the endogenous promoter. A potential explanation for this might be that SB-mediated IFN-g gene transfer was sufficient to initiate chemotaxis of antigen presenting cells such as microglia or dendritic cells, which in turn phagocytosed tumor antigen and evoked a T-cellmediated antitumor immune response. The enhanced infiltration of CD4 þ and CD8 þ lymphocytes in IFN-g- Sleeping beauty-enhanced cytokine gene therapy A Wu et al treated tumors (Figure 6 ), along with the increased abundance of tumor-reactive lymphocytes following IFN-g gene therapy (Figure 7a ), provide supporting evidence for this possibility. Accordingly, it is possible that tumor-infiltrating lymphocytes secreting IFN-g in SB-treated mice may account for the increase in endogenous IFN-g expression observed by RT-PCR (Figure 3) . Alternatively, the continued expression of vector-derived IFN-g in SB-treated mice may have simply caused reciprocating inflammation by peritumoral astrocytes and neurons, which could account for sustained expression of endogenous IFN-g in SB-treated mice. Finally, we cannot exclude the possibility that the SB transposase protein itself may also be immunogenic, acting as an adjuvant, and that could explain why only SB-treated tumors exhibited sustained expression of the endogenous IFN-g mRNA.
In this study, we also report the development of the GL261-Luc glioma cell line, which appears to be useful to measure tumor burden by bioluminescent imaging. GL261-Luc is genetically engineered to stably express firefly luciferase regulated by the CLP promoter. One important observation about this cell line is that injection of dozens of animals with an identical dose of cells (10 000) resulted in variable photon emission 1 day later (Figures 4a and 5a) . Although experimental error in the actual number of cells delivered might partially explain this, the injections were administered by skilled personnel using a single cell suspension. This imaging relies on visible light to penetrate through tissue. Therefore, it is likely that partial reflux of cells nearer to the cortex, or differences in the diameter of the bur hole in the skull may enhance measured photons; this may vary between animals. In addition, the number of cells that actually survive in the brain during the first 24 h is likely to vary between animals. Nevertheless, tumor burden measured by imaging correlated with survival time in this study (i.e., signal above 3 Â 10 7 photons/s cm 2 consistently correlated with neurological deficits and finally morbidity). Only mice treated with IFN-g or IFN-g and CpG exhibited tumor regression measured by imaging, and this positively correlated with survival (Figures 4 and 5) . One potential concern in using GL261-Luc for immunotherapy studies is that expression of luciferase might increase the immunogenicity of the cells. Although we cannot exclude this possibility, there was no difference in tumor-reactive lymphocytes measured by ELISPOT from IFN-g-treated mice, regardless of stimulation with parental GL261 or GL261-Luc cells (Figure 7b) . Moreover, the survival of untreated animals bearing GL261-Luc tumors was nearly identical to that reported by Andaloussi et al. 25 using the parental GL261 cell line. Regardless of these potential limitations, GL261-Luc may be useful to study the time dynamics of tumor regression in response to immunotherapy in vivo and in real-time. This could potentially yield important information when correlated with repeated gene transfer or vaccinations, or to delineate the relationship between the levels of circulating CD4 þ CD25 þ Fox3p þ regulatory T cells and tumor response.
It is important to consider that the survival benefit of SB-mediated IFN-g gene therapy observed in this study is very similar to that reported by Ehtesham et al. 17 using adenoviral-mediated IFN-g gene therapy to treat intracranial GL26 tumors. Both studies showed a statistically significant increase in survival compared with controls, but no sustained cure (long-term survival). The lack of long-term tumor regression in these studies indicates that IFN-g gene transfer as a monotherapy is not effective enough to translate into human trials. Nevertheless, both adenoviral and SB vectors have been used to cause sustained tumor regression when more effective therapeutic genes are delivered.
2,3 SB offers an important advantage characteristic to viral vectors (i.e., long-term expression), whereas still retaining the amenability to large-scale manufacture that makes nonviral vectors attractive.
The results reported in the current study using CpG ODN 2006 are consistent with those of Andaloussi et al. (Figure 6b) , and modestly enhanced tumorreactive lymphocyte activity measured by ELISPOT (Figure 7a ). Although intratumoral infusion of CpG has shown curative effects using central nervous system-1 (CNS-1) rat glioma model, 24 a phase I human trial for GBM was not as promising. 29 In this trial, two tumor responses were observed and all patients died owing to tumor progression. Seizure was also common in this clinical trial, 30 but it was difficult to determine if disease or CpG treatment was the cause. We found that intratumoral injection of 5 mg of CpG was well tolerated, but doses above 15 mg caused seizure in 100% of mice (not shown). Furthermore, Deng et al. found that intracisternal injection of CpG DNA can cause meningitis in rodents. 31 The specific CpG sequence, purity and method of administration likely play a role in side effects; such subtleties may account for differences observed when administering CpG ODN into the brain. Studies that address the long-term side effects of direct intracerebral injection of CpG ODN into the brain are warranted, and our results indicate caution should be taken in future applications.
We recently demonstrated that CD133 þ human GBM cells, which have been identified as tumor-renewing cancer stem cells, 32 downregulate MHC I and many activating ligands important in NK cell-mediated lysis. It was also found that IFN-g partially restores their immunogenecity. 33 One potential application of in situ IFN-g gene transfer may be to increase the immunogenicity of glioma stem cells and their differentiated daughter tumor cells, and potentiate migration of tumor infiltrating lymphocytes, in combination with a peripheral vaccination. A similar approach was recently validated by Kuwashima et al.; they utilized delivery of dendritic cells engineered to secrete IFN-a into the brain of tumor-bearing mice and demonstrated enhanced efficacy of a peripheral tumor cell vaccine. 34 Experiments that examine the synergistic effects of in situ cytokine gene transfer and peripheral vaccination are a future direction of the current study. SB and other recombinase systems may be useful to increase long-term gene expression within the tumor using plasmid vectors, and thereby enhance therapeutic efficacy.
